(deh-SY-tuh-been … SEE-daz-YOOR-ih-deen)
This page contains brief information about decitabine and cedazuridine and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Decitabine and cedazuridine is approved to treat adults with:
- Myelodysplastic syndromes (MDS), including chronic myelomonocytic leukemia (CMML).
Decitabine and cedazuridine is also being studied in the treatment of other types of cancer.
Decitabine and cedazuridine is a tablet form of decitabine combined with cedazuridine. For more information about the form of decitabine that is given by infusion, see the Drug Information Summary for Decitabine.
More About Decitabine and Cedazuridine
Definition from the NCI Drug Dictionary – Detailed scientific definition and other names for this drug.
More About Decitabine and Cedazuridine – A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Clinical Trials Accepting Patients
Find Clinical Trials for Decitabine And Cedazuridine – Check for trials from NCI’s list of cancer clinical trials now accepting patients.
